Celestial Therapeutics has been accepted into Johnson & Johnson Innovation – JLABS as a resident company at its flagship site in San Diego, California. Michael Houghton, a Nobel Prize winner in Physiology or Medicine, has joined Celestial's Scientific Advisory Board. The company's strategic approach focuses on developing safer, more efficacious mRNA therapeutics with support from leading academic and industry partners.
Cyborg Score Rationale
Celestial Therapeutics demonstrates solid early-stage potential with validated intellectual property licensed from Harvard, world-class scientific advisors including a Nobel laureate, and institutional backing from J&J Innovations. However, as a very early-stage private biotech (founded October 2019 with minimal staff), the company faces typical preclinical-stage risks including lengthy clinical development timelines, capital intensity, and regulatory uncertainties.
Top Insights
Founded October 2019 with a proprietary mRNA platform technology licensed from Harvard.
Lead dual modal antiviral/anti-inflammatory therapeutic, CT-02, is advancing into human clinical trials for viral myocarditis treatment via Mayo Clinic Innovation Exchange partnership.
Investors include National Institute of Allergy and Infectious Diseases, Red Bear Angels, Endless Frontier Labs, and StartX.
George Church, a Professor at Harvard and MIT, has joined Celestial's Scientific Advisory Board.
Named Competitors
Moderna — mRNA vaccine and therapeutic platform
BioNTech — mRNA-based immunotherapies and vaccines
CureVac — mRNA therapeutic platform
Recent Developments
Mayo Clinic Innovation Exchange partnership advancing CT-02 for viral myocarditis into human trials (timeframe not specified in available sources)
J&J Innovations JLABS residency at San Diego site (timeframe not specified in available sources)